Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

18.45 +0.01 (+0.05%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries ADR

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
24 25 Next >
Geopolitical Risks Prevail
A discussion about current geopolitical risks and their impact on commodity and stock markets. 
Via Talk Markets
ADHD Medication Shortage Worsens, Vyvanse Supply Dwindles Amid Adderall Scarcity
The supply of an alternative to Adderall, Vyvanse (lisdexamfetamine), a commonly used medication for Attention-deficit/hyperactivity disorder (ADHD), is dwindling, further limiting options for patients... 
Via Benzinga
3 Bargain Stocks to Buy on the Dip
These stocks should be poised to rebound. 
Via The Motley Fool
Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patients
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reaches Agreement With Kentucky to Settle the State’s Price Fixing Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
Why Teva Pharmaceutical Stock Is Jumping Today
Investors are reacting positively to Teva's new growth strategy. 
Via The Motley Fool
Teva Pharma Crumbles After First-Quarter Earnings Miss, Flat Sales
Teva reported absolutely flat sales in the first quarter and light earnings. 
Via Investor's Business Daily
Drug Shortages in Focus: How FDA's Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape
The FDA is actively seeking new suppliers to address the shortages of methotrexate, a widely used cancer drug in short supply since March.  Methotrexate is an injected medication utilized to treat... 
Via Benzinga
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
From Teva Pharmaceutical Industries Limited
Via Business Wire
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
From Alvotech
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Is AbbVie or Amgen the Better Bargain Buy Right Now?
These elite drugmakers are both working through a number of headwinds. 
Via The Motley Fool
Teva Concludes Nationwide Opioids Settlement Agreement
From Teva Pharmaceutical Industries Limited
Via Business Wire
Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management
From Phil Inc.
Via Business Wire
Teva Pharmaceuticals Just Made a Big Announcement, but Is It a Buy?
It's unclear whether the pivot will be enough to halt its recent decline. 
Via The Motley Fool
Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2023
Via Benzinga
Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Via Benzinga
Why Is Alimera Sciences (ALIM) Stock Up 21% Today?
Alimera Sciences (ALIM) stock is taking off on Thursday after signing a major deal with EyePoint Pharmaceuticals (EYPT). 
Via InvestorPlace
Why Is Teva Pharmaceuticals (TEVA) Stock Up Today?
Teva Pharmaceuticals (TEVA) stock is climbing higher on Thursday after the pharmaceutical company announced a new growth strategy. 
Via InvestorPlace
Netflix, Synopsys, Madison Square Garden Entertainment And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mixed, with the Dow Jones dropping around 50 points on Thursday. Here are some big stocks recording gains in today’s session. Urstadt Biddle Properties Inc. (NYSE: UBP) shares surged... 
Via Benzinga
Teva Launches New “Pivot to Growth” Strategy
From Teva Pharmaceutical Industries Limited
Via Business Wire
Apple Thwarts $2B In Fraud Transactions, UBS Takes $17B Hit From 'Hasty Credit Suisse Takeover,' Verizon Streamlines Unlimited Data Plans: Today's Top Stories
Benzinga 
Via Benzinga
One More Quits US Pharma Lobby Group: AstraZeneca Follows Teva, AbbVie Footsteps
AstraZeneca Plc (NASDAQ: AZN) has decided to leave a U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), making it the third company to leave the group in the last... 
Via Benzinga
A Bitter Pill to Swallow: Teva's $235M Challenge to GSK Dismissed by Supreme Court
The U.S. 
Via Benzinga
AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Teva Pharmaceutical Industries (TEVA) Q1 2023 Earnings Call Transcript
TEVA earnings call for the period ending March 31, 2023. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.